600201 生物股份
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入970,805-20.36%1,598,2251,528,6691,776,3181,581,906
减:营业总成本775,774-13.45%1,257,5221,217,0581,329,0241,142,130
    其中:营业成本425,238-13.26%652,246685,275677,127607,495
               财务费用(37,892)-7.93%(56,151)(46,028)(40,451)(19,573)
               资产减值损失(14,664)84.42%(35,665)(77,038)(51,730)(14,163)
公允价值变动收益275-333.61%(5,942)(4,503)(3,221)8,476
投资收益(6,936)1,456.43%(1,836)(5,311)6,41124,006
    其中:对联营企业和合营企业的投资收益(7,005)1,471.98%(580)(1,447)(1,127)1,261
营业利润193,866-41.41%315,209255,099414,660477,754
利润总额193,586-41.47%315,831245,585413,275476,215
减:所得税费用23,330-48.16%38,73445,46324,26553,825
净利润170,256-40.42%277,097200,121389,009422,390
减:非控股权益715-128.03%(6,533)(10,539)6,72216,195
股东净利润169,541-41.19%283,631210,660382,287406,195

市场价值指针
每股收益 (元) *0.150-42.31%0.2600.1900.3400.360
每股派息 (元) *----0.0800.0600.1100.120
每股净资产 (元) *4.8451.95%4.7904.5274.6814.423
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容